Kiniksa Pharmaceuticals, Ltd. KNSA

$ 20.49 -0.51%

Quarterly report 2024-Q3
added 10-29-2024

Kiniksa Pharmaceuticals, Ltd. Balance Sheet 2011-2024 | KNSA

Annual Balance Sheet Kiniksa Pharmaceuticals, Ltd.

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-95.7 M	-117 M	-116 M	-107 M	-46.9 M	-72 M	-45.6 M	-56 M	-	-	-	-	-
Long Term Debt	10 M	2.62 M	2.67 M	4.88 M	-	-	-	-	-	-	-	-	-
Long Term Debt Current	2.25 M	3.3 M	3.38 M	2.11 M	1.7 M	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	1.28 M	144 K	120 M	79.9 M	-	-	-	-	-
Total Current Liabilities	63.7 M	47.1 M	44.8 M	31.8 M	27.8 M	42.6 M	-	-	-	-	-	-	-
Total Liabilities	87.5 M	63.5 M	47.8 M	37.5 M	29.1 M	42.7 M	137 M	82.2 M	-	-	-	-	-
Deferred Revenue	307 K	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-478 M	-492 M	-675 M	-517 M	-356 M	-194 M	-91 M	-26.1 M	-	-	-	-	-
Total Assets	526 M	460 M	233 M	349 M	255 M	322 M	47.5 M	56.5 M	-	-	-	-	-
Cash and Cash Equivalents	108 M	123 M	122 M	114 M	46.9 M	72 M	45.7 M	-	-	-	-	-	-
Book Value	439 M	396 M	185 M	312 M	225 M	279 M	-89.7 M	-25.7 M	-	-	-	-	-
Total Shareholders Equity	439 M	396 M	185 M	312 M	225 M	279 M	-89.7 M	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Kiniksa Pharmaceuticals, Ltd.

	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	8.56 M	9.32 M	9.86 M	10.7 M	11.3 M	2.13 M	2.62 M	3.44 M	-	2.1 M	2.67 M	3.5 M	3.5 M	4.2 M	4.88 M	4.88 M	4.88 M	4.88 M	955 K	955 K	955 K	955 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	118 M	107 M	87.8 M	77.9 M	72.7 M	52.8 M	63.5 M	75.9 M	-	64.7 M	47.8 M	38.8 M	43.4 M	40.5 M	37.5 M	37.5 M	37.5 M	37.5 M	29.1 M	29.1 M	29.1 M	29.1 M	42.7 M	42.7 M	42.7 M	42.7 M	17.4 M	17.4 M	17.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	12 K	156 K	2.56 M	4.67 M	6.5 M	-	12.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-512 M	-500 M	-496 M	-503 M	-489 M	-504 M	-492 M	-496 M	-	-701 M	-675 M	-639 M	-609 M	-567 M	-517 M	-517 M	-517 M	-517 M	-356 M	-356 M	-356 M	-356 M	-194 M	-194 M	-194 M	-194 M	-91 M	-91 M	-91 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	555 M	542 M	520 M	483 M	484 M	443 M	460 M	460 M	-	231 M	233 M	253 M	279 M	311 M	349 M	349 M	349 M	349 M	255 M	255 M	255 M	255 M	322 M	322 M	322 M	322 M	47.5 M	47.5 M	47.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	97.4 M	99.3 M	141 M	118 M	113 M	80.6 M	123 M	176 M	94.3 M	63.3 M	122 M	190 M	168 M	120 M	114 M	114 M	114 M	114 M	46.9 M	46.9 M	46.9 M	46.9 M	72 M	72 M	72 M	72 M	45.6 M	45.6 M	45.6 M	-	56.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	437 M	435 M	432 M	405 M	412 M	390 M	396 M	384 M	-	166 M	185 M	214 M	236 M	271 M	312 M	312 M	312 M	312 M	225 M	225 M	225 M	225 M	279 M	279 M	279 M	279 M	30.1 M	30.1 M	30.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	437 M	435 M	432 M	405 M	412 M	390 M	396 M	384 M	153 M	166 M	185 M	214 M	236 M	271 M	312 M	312 M	312 M	312 M	225 M	225 M	225 M	225 M	279 M	279 M	279 M	279 M	-89.7 M	-89.7 M	-89.7 M	-	-25.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency